$LONA

LeonaBio, Inc.

LeonaBio is a clinical-stage biopharmaceutical company developing drug candidates for treatment-resistant metastatic breast cancer, amyotrophic lateral sclerosis (ALS) and other neurological conditions. Its pipeline includes lasofoxifene, an oral small-molecule therapy being evaluated in a Phase 3 trial for metastatic breast cancer with ESR1 mutations, and ATH-1105, a small molecule designed to modulate the neurotrophic HGF system and being developed for ALS. The company has also studied ATH-1020 for neurological indications and has early compounds targeting other molecular targets. LeonaBio develops programs internally and acquires or in-licenses drug rights. It aims to commercialize candidates following regulatory approval and is reviewing partnership or other arrangements. LeonaBio is based in Bothell, Washington.

1
1
2
—
—
Portman David J.
0%
See all $LONA insider activity →
Med

Mizuho cuts LeonaBio stock price target on financing concerns

Mizuho reduced its price target for LeonaBio (LONA) to $12 from $13, citing financing concerns after warrants expired unexercised. The stock is down 29% this week. Mizuho maintains an Outperform rating, noting progress in the ELAINE-3 study and a supportive investor base. LeonaBio reported Q3 2026 results, confirming trial enrollment completion by year-end 2026. Other analysts also adjusted price targets.

Citizens cuts LeonaBio stock price target to $16 on valuation

Citizens reduced its price target for LeonaBio (NASDAQ:LONA) to $16 from $17, keeping a Market Outperform rating. The stock is at $3.23, down 20% in a week. The firm expects trial enrollment to complete by Q4 2026 and Phase 3 results by H2 2027. LeonaBio reported Q3 2026 cash of $32M and a Q2 loss of $0.80 per share, better than expected. Mizuho also lowered its target to $15, citing higher expenses.

Athira Pharma GAAP EPS of -$0.89 misses by $0.20

Athira Pharma reported a Q3 GAAP EPS of -$0.89, missing estimates by $0.20. The company's cash position decreased to $32.3M as of September 30, 2026, from $88.3M at the end of 2025, with net cash used in operations rising to $18.98M for the quarter, up from $4.7M a year prior.

LONA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning LONA (LeonaBio, Inc.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 2 bearish.

Recent LONA coverage spans earnings, financial news and corporate actions.

In the last 30 days, LONA insiders filed 1 SEC Form 4 transaction — 1 purchase and no sales. The most active reporter was Portman David J. with 1 filing.

What's driving LONA

  • Analyst downgrade and financing concerns may push the stock lower.

    investing.com · Nov 18, 2026

  • Analyst valuation reset without changing core clinical timelines, but the lower target can pressure near-term sentiment and trading multiples.

    investing.com · Nov 17, 2026

  • Earnings miss plus deteriorating liquidity likely increases near-term financing and burn-rate concerns.

    seekingalpha.com · Nov 16, 2026

  • The filing updates near-term clinical execution risk (ELAINE-3 enrollment completion) and reinforces the company’s timeline toward 2H 2027 topline, which can shift biotech risk pricing.

    SEC EDGAR 8-K · Nov 16, 2026

  • Large insider purchase signals confidence and may drive short‑term buying pressure.

    SEC EDGAR · Oct 29, 2026

AlphAI scores every news story that mentions LONA with an AI model for sentiment and relevance, and aggregates insider trades from LeonaBio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $LONA

Score

Mizuho cuts LeonaBio stock price target on financing concerns

Mizuho reduced its price target for LeonaBio (LONA) to $12 from $13, citing financing concerns after warrants expired unexercised. The stock is down 29% this week. Mizuho maintains an Outperform rating, noting progress in the ELAINE-3 study and a supportive investor base. LeonaBio reported Q3 2026 results, confirming trial enrollment completion by year-end 2026. Other analysts also adjusted price targets.

Citizens cuts LeonaBio stock price target to $16 on valuation

Citizens reduced its price target for LeonaBio (NASDAQ:LONA) to $16 from $17, keeping a Market Outperform rating. The stock is at $3.23, down 20% in a week. The firm expects trial enrollment to complete by Q4 2026 and Phase 3 results by H2 2027. LeonaBio reported Q3 2026 cash of $32M and a Q2 loss of $0.80 per share, better than expected. Mizuho also lowered its target to $15, citing higher expenses.

$LONAMedEarnings

LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Da

$LONAMedOffering· 23.03M · closed

In December 2025, as part of a private placement, LeonaBio, Inc. issued warrants to purchase an aggregate of 23,031,494 shares of its common stock

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. In December 2025, as part of a private placement, LeonaBio, Inc. (the “Company”) issued warrants to purchase an aggregate of 23,031,494 shares of its common stock (the “Series A Common Warrants”). The Series A Common Warrants have an exercise price of $6.3

Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB)

Analysts from Piper Sandler and Cantor Fitzgerald maintained Buy ratings on NeoGenomics (NEO), LeonaBio (LONA), and Solid Biosciences (SLDB). NeoGenomics has a $21.00 target, LeonaBio a $20.00 target, and Solid Biosciences a $26.00 target. Consensus ratings are Moderate Buy for NEO and Strong Buy for LONA and SLDB, with respective average targets of $18.33, $17.33, and $19.17.

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

LeonaBio (NASDAQ:LONA) reported a Q2 loss of $0.80 per share, smaller than analysts’ $1.12 forecast. Net loss rose to $19.0 million from $7.0 million a year earlier. Phase 3 ELAINE-3 enrollment nears 600 target, with 495 patients enrolled and topline results expected in H2 2027. Cash fell to $51.1 million from $88.3 million.

$LONAMedEarnings

LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline D

$LONALowShareholder vote

LeonaBio, Inc. (LONA): Submission of Matters to a Vote of Security Holders

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001620463 0001620463 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,

Related tickers